INOV's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 839.83 -- higher than 96.11% of US-listed equities with positive expected earnings growth.
With a price/earnings ratio of 355.38, Inovalon Holdings Inc P/E ratio is greater than that of about 97.85% of stocks in our set with positive earnings.
The price/operating cash flow metric for Inovalon Holdings Inc is higher than 88.12% of stocks in our set with a positive cash flow.
Stocks with similar financial metrics, market capitalization, and price volatility to Inovalon Holdings Inc are CUB, ORBC, SPB, CE, and SYNH.
INOV's SEC filings can be seen here. And to visit Inovalon Holdings Inc's official web site, go to www.inovalon.com.
Inovalon Holdings provides advanced cloud-based data analytics and data-driven intervention platforms to the healthcare industry in the United States. The company was founded in 1998 and is based in Bowie, Maryland.
INOV Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for INOV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Inovalon Holdings Inc ranked in the 11th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 89.67%. The most interesting components of our discounted cash flow analysis for Inovalon Holdings Inc ended up being:
Its compound free cash flow growth rate, as measured over the past 5.33 years, is -0.01% -- higher than only 24.37% of stocks in our DCF forecasting set.
Inovalon Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
The weighted average cost of capital for the company is 9. This value is greater than 73.42% stocks in the Technology sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Technology that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as INOV, try EVOP, INIS, ITRI, SPOT, and TTD.
Investors do not wait. Get ready for Active Management now! Now is the time for investors to incorporate quantitative tools to empower their portfolio management. Any change in the direction of any of the principal components of earnings growth such as sales growth, gross margins, operating or financing costs, may be important indicators about future direction […] The post Inovalon Holdings: Resilient Growth Within Healthcare appeared first on ValueWalk .
Retailer’s Specialty Pharmacy Business to Implement ScriptMed® Cloud Solution to Empower Enhanced Outcomes and Economics for its CustomersBOWIE, Md., July 23, 2020 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced a long-term engagement with Walmart’s Specialty Pharmacy business (NYSE: WMT) to provide cloud-based capabilities through the Inovalon ONE® Platform as part of its data-driven strategy to improve outcomes and economics for its customers. The high-complexity and high-cost nature of specialty pharmacy stands to benefit significantly from the capabilities enabled through the Inovalon ONE® Platform. Through the implementation of ScriptMed® Cloud, a software-as-a-service (SaaS) cloud offering...